Tesamorelin and sermorelin are synthetic peptides that interact with the growth hormone-releasing hormone (GHRH) pathway. Both can stimulate the pituitary gland to release endogenous growth hormone (GH), which makes them relevant to research involving the GHRH–GH axis.
However, they are not identical or interchangeable. They differ in terms of structure, development, and regulation. This knowledge is key when it comes to the comparison of tesamorelin and sermorelin in scientific research. For a closer look, see our overview of tesamorelin vs. CJC-1295.
Tesamorelin vs Sermorelin: Key Differences
| Feature | Tesamorelin | Sermorelin |
| Peptide class | GHRH/GHRF analogue | GHRH analogue |
| Primary action | Stimulates endogenous GH release | Stimulates endogenous GH release |
| Major research focus | Visceral adipose tissue and body composition | GH secretion and GH-deficiency research |
| Current FDA-approved product | Yes, for a specific indication | No current FDA-approved marketed product |
| Historical clinical research | HIV-associated lipodystrophy | Growth hormone deficiency |
| Approved for general weight loss | No | No |
The important point is that these peptides share a pathway but have different evidence bases.
What is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing factor analogue that stimulates the pituitary gland to release endogenous growth hormone.
Its best-established clinical application is the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. According to the FDA EGRIFTA SV prescribing information, tesamorelin is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The same label specifically states that it is not indicated for weight-loss management.
That distinction matters because tesamorelin is sometimes described online as a general weight-loss peptide. Its FDA-approved indication is much narrower.
Clinical trials have demonstrated a measurable effect on visceral adipose tissue. Falutz et al. found that tesamorelin reduced visceral adipose tissue compared with placebo in HIV-infected patients with excess abdominal fat. The study also showed that the reduction was not maintained after treatment was discontinued.
Another randomized trial found that tesamorelin reduced visceral adipose tissue and liver fat in HIV-infected patients with abdominal fat accumulation. Stanley et al. reported significant reductions in visceral adipose tissue and liver fat following six months of tesamorelin treatment.
These findings make tesamorelin particularly relevant to research involving visceral adiposity, abdominal fat distribution, body composition, and metabolic effects associated with visceral fat.
What is Sermorelin?
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human GHRH. Instead of directly providing growth hormone, it stimulates the pituitary gland to release endogenous GH.
Prakash and Goa describe sermorelin as a 29-amino-acid analogue of human GHRH and the shortest synthetic peptide retaining the full biological activity of GHRH.
Sermorelin has a substantial historical research record. Earlier studies examined its ability to stimulate GH secretion and investigated its potential use in children with idiopathic growth hormone deficiency.
Its pharmacokinetic profile is also relatively short. Esposito et al. reported a short plasma half-life for the peptide, reflecting rapid clearance and degradation.
Sermorelin was historically marketed in the United States as Geref. However, its regulatory history should be distinguished from its historical clinical use. FDA later determined that the products had not been withdrawn from sale for reasons of safety or effectiveness.
Therefore, historical FDA approval should not be confused with a currently marketed FDA-approved sermorelin product.
How Are Tesamorelin and Sermorelin Similar?
The main similarity is their relationship with the GHRH–GH axis.
These peptides stimulate the body’s endogenous secretion of growth hormone, unlike recombinant GH, which directly supplies a laboratory-produced form of the hormone.
In fact, differences in their composition and development history could influence factors such as pharmacodynamics, duration of action, receptor interactions, and the physiological effects studied in research.
For this reason, tesamorelin and sermorelin cannot be considered completely interchangeable compounds.
Tesamorelin vs Sermorelin for Fat Loss
Tesamorelin vs sermorelin for weight loss is a common search query, but the scientific answer requires careful wording.
Tesamorelin has considerably stronger clinical evidence for reducing visceral adipose tissue, particularly in people with HIV-associated abdominal fat accumulation. Multiple randomized trials have investigated this effect. This is covered further in our guide to what to look for in a tesamorelin source.
The FDA prescribing information for EGRIFTA SV makes an important distinction: tesamorelin is indicated for reducing excess abdominal fat in a specific HIV-associated population, but it is not indicated for weight-loss management.
However, sermorelin has a substantially different evidence base. The historical clinical research on sermorelin was mainly aimed at growth hormone deficiency rather than visceral fat reduction based on comparable randomized evidence.
Thus, the simplification of both peptides as competing “fat-loss peptides” does not capture the research adequately.
FDA Approval and Regulatory Status
Tesamorelin and sermorelin have particularly different regulatory histories.
The FDA-approved EGRIFTA SV identifies tesamorelin as a growth hormone-releasing factor analogue approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
Sermorelin has a different regulatory position. The FDA Federal Register record documents the withdrawal of the product’s approvals after discontinuation. Thus, historical FDA approval should not be interpreted as current FDA approval of a marketed sermorelin drug product.
This distinction is especially important when evaluating information about compounded peptides or research materials.
Safety and Research Considerations
Tesamorelin influences the GH/IGF-1 pathway, so its effects extend beyond changes in body composition. The FDA prescribing information for EGRIFTA SV includes warnings and precautions concerning elevated IGF-1, glucose intolerance, fluid retention, joint-related symptoms, injection-site reactions, and hypersensitivity.
Sermorelin should also not automatically be described as “safe” simply because it stimulates endogenous GH. Historical research reported adverse effects such as injection-site discomfort and transient flushing. Current compounded products should not be presented as equivalent to an FDA-approved finished drug. We stock Sermorelin 10mg research vial for laboratory use.
For research applications, peptide identity, purity, formulation, storage, analytical characterization, and experimental conditions can all influence the interpretation of results. You can check purity and identity data for each lot on our COA page.
Which is Better: Tesamorelin or Sermorelin?
There is no universal winner.
If the comparison is based on current regulatory status and clinical evidence for visceral adipose tissue, tesamorelin has the stronger evidence base. It has a specific FDA-approved indication and has been evaluated in multiple randomized clinical trials.
Sermorelin has a different research profile. It is more closely associated with GHRH physiology, endogenous GH secretion, and historical growth hormone-deficiency research.
The better comparison therefore depends on the research question. Tesamorelin is particularly relevant to research involving visceral adiposity and HIV-associated lipodystrophy, while sermorelin is more closely associated with GH-secretory physiology.
FAQs
Q1. Is tesamorelin the same as sermorelin?
No. Both are related to GHRH and stimulate endogenous GH secretion, but they are structurally different peptides with different clinical and regulatory histories.
Q2. Is tesamorelin FDA approved?
Yes. The FDA prescribing information for EGRIFTA SV states that tesamorelin is approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not approved as a general weight-loss treatment.
Q3. Is sermorelin FDA approved?
Sermorelin had historical FDA-approved products, but those products were discontinued, and their approvals were withdrawn. Therefore, historical approval should not be interpreted as current approval of a marketed sermorelin product.
Q4. Which peptide is better for visceral fat research?
Tesamorelin has the stronger clinical evidence for reducing visceral adipose tissue, particularly in the population covered by its FDA-approved indication.
Conclusion
Tesamorelin and sermorelin act through the GHRH–GH pathway, but they differ in chemical structure, scientific history, evidence base, and regulatory status.
Tesamorelin has a substantial clinical evidence base for reducing visceral adipose tissue in HIV-associated lipodystrophy, while sermorelin has a long research history involving GHRH stimulation and growth hormone deficiency. We go into more detail in our guide to how sermorelin and ipamorelin differ.
The important issue here is not just which one of the peptides is better. The important point is what biological questions were asked and what kind of evidence was gathered.
References
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf
- https://pubmed.ncbi.nlm.nih.gov/20101189/
- https://pubmed.ncbi.nlm.nih.gov/25038357/
- https://pubmed.ncbi.nlm.nih.gov/18031173/
- https://pubmed.ncbi.nlm.nih.gov/14499707/
- https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/FR-2013-03-04.pdf
